Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats

Neuroreport. 1998 Sep 14;9(13):2985-8. doi: 10.1097/00001756-199809140-00012.

Abstract

THE NMDA receptor antagonist phencyclidine (PCP) has low micromolar affinity for the 5-HT reuptake site, but it is uncertain whether PCP blocks 5-HT reuptake when given systemically to rats in behaviourally stimulating doses. We here report for the first time that systemically administered PCP (5 mg/kg, s.c.) increases extracellular 5-HT levels in the rat medial prefrontal cortex (to 322%) and dorsal hippocampus (to 233%). Increases were found also when citalopram (1 microM) was included in the perfusion medium (to 184 and 180%, respectively). Extracellular 5-HIAA concentrations increased during both conditions, and extracellular GABA decreased in the dorsal hippocampus. It is concluded that systemic PCP treatment elevates extracellular 5-HT levels, probably through mechanisms other than a blockade of 5-HT reuptake.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Chemistry / drug effects
  • Citalopram / administration & dosage
  • Citalopram / pharmacology
  • Dialysis Solutions / chemistry
  • Drug Administration Routes
  • Extracellular Space / chemistry*
  • Hippocampus / chemistry
  • Hippocampus / drug effects
  • Hydroxyindoleacetic Acid / analysis
  • Injections, Subcutaneous
  • Male
  • Microdialysis*
  • Perfusion
  • Phencyclidine / administration & dosage
  • Phencyclidine / pharmacology*
  • Prefrontal Cortex / chemistry
  • Prefrontal Cortex / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Serotonin / analysis
  • Serotonin / biosynthesis*
  • Wakefulness
  • gamma-Aminobutyric Acid / analysis

Substances

  • Dialysis Solutions
  • Citalopram
  • Serotonin
  • Hydroxyindoleacetic Acid
  • gamma-Aminobutyric Acid
  • Phencyclidine